Abstract:BackgroundCongenital cytomegalovirus (CMV) infection is the leading cause of non-genetic sensorineural hearing loss (SNHL) in childhood. Treatment of infants with symptomatic congenital CMV disease with intravenous (IV) ganciclovir or oral valganciclovir improves audiologic outcomes when started in the first month of age. Neutropenia is the most common adverse event of antiviral treatment, occurring in 19-63% of infants. No correlation between ganciclovir drug exposure and development of neutropenia has been identified.MethodsWe utilized pharmacokinetic (PK), pharmacodynamic (PD), and hematologic data from three international, NIH-funded studies of IV ganciclovir or oral valganciclovir conducted by the Collaborative Antiviral Study Group (CASG) from 2002-2018. Drug exposure was estimated using area-under-the-curve (AUC) values and was defined as high (AUC≥40 mg•hr/mL) or low (AUC 1000 cells/mm 3 ) or low (ANC≤1000 cells/mm 3 ) and regularly monitored for development of neutropenia (ANC<800 cells/mm 3 ). Ordinal logistic regression determined if AUC or baseline ANC was a predictor of neutropenia severity across the course of treatment. Time to neutropenia was defined as the first study day that a participant had an ANC<800. Median time to neutropenia was determined using nonparametric estimates for each group of subjects and Kaplan-Meier curves were created. Fisher's Exact Test compared proportions.Results139 subjects were included. Neither AUC nor baseline ANC were significant predictors of neutropenia severity using ordinal logistic regression (P=0.62, P=0.35, respectively). However, a greater proportion of subjects with a baseline low ANC developed neutropenia (75% vs 40%, P=0.004; Odds Ratio 1.9, 95% CI 0.48-7.67). Subjects with a baseline low ANC also developed neutropenia more quickly than those with a baseline high ANC (Figure 1, median of 1.5 vs 216 days, P<0.0001), as did subjects with high drug exposure compared with low drug exposure (median of 28 vs 215 days, P=0.08). When considering only subjects with low baseline ANC, median time to neutropenia development was similar in those with low versus high drug exposure (median of 1 vs 2 days, P=0.23). These findings are limited by 50% of the 16 subjects with low baseline ANC being neutropenic on day 1. Likewise, drug exposure made no difference in time to development of neutropenia in subjects with high baseline ANC (P=0.36). All 3 subjects with high drug exposure and low baseline ANC developed neutropenia.ConclusionLow ANC at baseline was correlated with the development of neutropenia in patients treated for symptomatic congenital CMV disease. High drug exposure hastened the development of neutropenia compared with low drug exposure. Further studies should investigate if different dosing regimens such as body weight versus body surface area affect development of neutropenia. Figure 1. Kaplan-Meier Curve of Neutropenia Development by Baseline ANC.

Evaluation of serum granulocyte colony stimulating factor levels in infants of preeclamptic mothers

Predictive significance of neutrophil-to-lymphocyte and platelet-to-lymphocyte for cytomegalovirus infection in infants less than 3 months: A retrospective study

Elevation of granulocyte-macrophage colony-stimulating factor in the placenta and blood in preeclampsia

Levels of neopterin and C-reactive protein in pregnant women with fetal growth restriction

Case report: Granulocyte-macrophage colony-stimulating factor sargramostim did not rescue the neutrophil phenotype in two patients with JAGN1-mutant severe congenital neutropenia

Neutrophil activation and C-reactive protein concentration in preeclampsia

Plasma Gelsolin Level Predicts Acute Kidney Injury after Cardiopulmonary Bypass in Infants and Young Children

Galectin-1 Expression in the Serum and Placenta of Pregnant Women with Fetal Growth Restriction and Its Significance

Impact of different genetic mutations on granulocyte development and G-CSF responsiveness in congenital neutropenia

The Relationship Between the Granulocyte-Stimulating Factor Level and White Blood Cell in the Cord Blood of Full Term Newborns

Increased levels of serum macrophage colony-stimulating factor before the onset of preeclampsia

A retrospective analysis of nadir-neutropenia directed pegylated granulocyte-colony stimulating factor on febrile neutropenia rates in (neo)adjuvant breast cancer chemotherapy regimens

Cytokine profile as diagnostic and prognostic factor in neonatal sepsis

Evaluation of recombinant human granulocyte colony-stimulating factor (rhG-CSF) therapy in granulopoetic patients complicated with sepsis

Relationship Between Granulocyte-Macrophage Colony-Stimulating Factor, Embryo Quality, and Pregnancy Outcomes in Women of Different Ages in Fresh Transfer Cycles: a Retrospective Study.

Elevation of serum macrophage colony-stimulating factor before the clinical manifestations of preeclampsia

The Role of Granulocyte Colony Stimulating Factor in Mitigating the Risk of Recurrent Miscarriages: A Comprehensive Review and Meta-Analysis

Serum levels of macrophage colony stimulating, vascular endothelial, and placenta growth factor in relation to later clinical onset of pre-eclampsia and a small-for-gestational age birth

G-CSF: A vehicle for communication between trophoblasts and macrophages which may cause problems in recurrent spontaneous abortion

Association of Maternal Serum CRP, IL-6, TNF-α, Homocysteine, Folic Acid and Vitamin B12 Levels with the Severity of Preeclampsia and Fetal Birth Weight

Predictors of Neutropenia Secondary to Ganciclovir Exposure During Treatment of Congenital Cytomegalovirus Disease